Organon & Co. (NYSE:OGN - Get Free Report) reached a new 52-week high during trading on Tuesday . The stock traded as high as $13.76 and last traded at $13.7540, with a volume of 4583387 shares trading hands. The stock had previously closed at $13.75.
Analyst Ratings Changes
Several research firms have recently weighed in on OGN. BNP Paribas Exane reissued a "neutral" rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Piper Sandler raised shares of Organon & Co. from an "underweight" rating to a "neutral" rating and upped their price objective for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. Finally, Weiss Ratings downgraded shares of Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 3rd. Five investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Reduce" and a consensus price target of $11.40.
Get Our Latest Analysis on Organon & Co.
Organon & Co. Stock Up 0.0%
The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44. The business has a 50 day simple moving average of $13.56 and a 200 day simple moving average of $10.96. The company has a market capitalization of $3.61 billion, a price-to-earnings ratio of 17.86, a PEG ratio of 1.27 and a beta of 1.55.
Organon & Co. Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.'s payout ratio is currently 10.39%.
Hedge Funds Weigh In On Organon & Co.
Several hedge funds have recently bought and sold shares of the company. Cetera Investment Advisers increased its stake in Organon & Co. by 1.7% during the first quarter. Cetera Investment Advisers now owns 48,073 shares of the company's stock worth $288,000 after purchasing an additional 788 shares during the period. Integrated Wealth Concepts LLC boosted its stake in shares of Organon & Co. by 2.8% in the third quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company's stock valued at $626,000 after purchasing an additional 1,594 shares during the period. Rafferty Asset Management LLC grew its holdings in shares of Organon & Co. by 8.5% in the second quarter. Rafferty Asset Management LLC now owns 23,578 shares of the company's stock valued at $228,000 after purchasing an additional 1,847 shares in the last quarter. Bank of Nova Scotia grew its holdings in shares of Organon & Co. by 4.6% in the third quarter. Bank of Nova Scotia now owns 44,512 shares of the company's stock valued at $475,000 after purchasing an additional 1,947 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in shares of Organon & Co. by 87.8% in the fourth quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company's stock valued at $31,000 after purchasing an additional 2,033 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.
About Organon & Co.
(
Get Free Report)
Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.
In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
